Sandra M. Gurrola's most recent trade in Eterna Therapeutics Inc was a trade of 30 Common Stock done . Disclosure was reported to the exchange on June 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eterna Therapeutics Inc | Sandra M. Gurrola | Sr. VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2025 | 30 | 110 | - | - | Common Stock | |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Sr. VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2025 | 30 | 0 | - | - | Restricted Stock Units | |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Sr. VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to buy) | |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Sr. VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 437 | 1,365 | - | - | Common Stock | |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Sr. VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 437 | 437 | - | - | Restricted Stock Units | |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Sr. VP of Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.94 per share. | 21 Jun 2024 | 180 | 1,185 | - | 1.9 | 349 | Common Stock |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Sr. VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2024 | 80,000 | 80,000 | - | - | Stock Option (Right to buy) | |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Vice President of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2022 | 8,750 | 16,953 | - | - | Common Stock | |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Vice President of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2022 | 8,750 | 26,250 | - | - | Restricted Stock Units | |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Vice President of Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.48 per share. | 21 Jun 2022 | 3,586 | 13,367 | - | 0.5 | 1,709 | Common Stock |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Vice President of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 114,500 | 114,500 | - | - | Stock Option (Right to buy) | |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Vice President of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 35,000 | 35,000 | - | - | Restricted Stock Unit | |
| Eterna Therapeutics Inc | Sandra M. Gurrola | Former SVP of Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.67 per share. | 24 Mar 2021 | 6,094 | 21,617 | - | 2.7 | 16,271 | Common Stock |